If you are not happy with the results below please do another search
A new coronavirus variant that shares some similarities with a more transmissible and intractable variant discovered in South Africa is on the rise in New York City, researchers said on Feb. 24.
The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing Covid-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.
The United States expects to roll out 3 to 4 million doses of Johnson & Johnson’s Covid-19 vaccine during the first week of March, pending authorization from the Food and Drug Administration, White House Covid-19 response coordinator Jeff Zients said on Feb. 24.
Health communications agency Evoke KYNE announced the promotion of Michael Grela to Executive Vice President, Head of Reputation and Social Impact.
The COVID-19 pandemic has redefined what it means and what it takes to be a healthcare provider in a time of crisis. In a new study from McCann Health, the data from the original 2016 Truth About Doctors study was re-examined and updated, highlighting the need to focus on prioritizing the health and wellbeing of physicians to ultimately help foster a healthier public.
Many health experts believe that the Covid-19 vaccine candidate NVX-CoV237 from Novavax offers potential advantages over competitors including Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca-Oxford.
Bristol Myers Squibb announced plans for a new manufacturing plant in Devens, Mass., adding to the company’s cell therapy network.
The Biden administration will deliver more than 25 million masks to community health centers, food pantries and soup kitchens from March through May as part of the battle against the coronavirus pandemic, the White House said in a statement.
Europe’s drug regulator is evaluating South Korean drugmaker Celltrion’s Covid-19 antibody treatment, the third such drug against the disease to go under real-time review in the region.
Johnson & Johnson’s one-dose Covid-19 vaccine appeared safe and effective in trials, the U.S. Food and Drug Administration said, paving the way for approval for emergency use as soon as Feb. 26.